We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

230 hedge funds and large institutions have $561M invested in Nektar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

814% more call options, than puts

Call options by funds: $2M | Put options by funds: $219K

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

1% more funds holding

Funds holding: 227 → 230 (+3)

0.3% less ownership

Funds ownership: 6.53% → 6.24% (-0.3%)

5% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 74

19% less capital invested

Capital invested by funds: $693M → $561M (-$131M)

Holders
230
Holders Change
+3
Holders Change %
+1.32%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
70
Reduced
74
Closed
25
Calls
$2M
Puts
$219K
Net Calls
+$1.78M
Net Calls Change
-$1.41M

Top Buyers

1
BlackRock
BlackRock
New York
+$13.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.2M
3
Northern Trust
Northern Trust
Illinois
+$3.87M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.21M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$2.89M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$29.8M
2
MC
Maverick Capital
Texas
-$12.2M
3
GPP
Great Point Partners
Connecticut
-$10.7M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$4.33M
5
State Street
State Street
Massachusetts
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$2.07M -$50.6K -850 -2%
RPAM
27
Rhenman & Partners Asset Management
Sweden
$2.07M – – –
Two Sigma Advisers
28
Two Sigma Advisers
New York
$2.03M +$1.86M +31,274 +285%
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$1.82M +$65.8K +1,106 +3%
Legal & General Group
30
Legal & General Group
United Kingdom
$1.69M -$371K -6,234 -15%
State of New Jersey Common Pension Fund D
31
State of New Jersey Common Pension Fund D
New Jersey
$1.65M -$276K -4,639 -12%
AG
32
Algert Global
California
$1.52M +$172K +2,894 +10%
Walleye Capital
33
Walleye Capital
New York
$1.52M -$51.5K -865 -3%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$1.48M +$1.07M +18,007 +141%
GPP
35
Great Point Partners
Connecticut
$1.43M -$10.7M -180,145 -86%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.41M +$21.1K +354 +1%
ABG
37
Ally Bridge Group
New York
$1.39M +$1.72M +28,863 New
TCM
38
Tang Capital Management
California
$1.38M – – –
Axa
39
Axa
France
$1.29M – – –
Bank of America
40
Bank of America
North Carolina
$1.2M +$201K +3,371 +16%
Public Sector Pension Investment Board (PSP Investments)
41
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.1M – – –
GCM
42
Graham Capital Management
Connecticut
$1.04M +$272K +4,573 +27%
OQS
43
Occudo Quantitative Strategies
Florida
$999K +$85.7K +1,441 +7%
PP
44
PDT Partners
New York
$985K -$2.08M -34,970 -63%
Assenagon Asset Management
45
Assenagon Asset Management
Luxembourg
$958K – – –
New York State Teachers Retirement System (NYSTRS)
46
New York State Teachers Retirement System (NYSTRS)
New York
$862K -$6.96K -117 -0.6%
Tudor Investment Corp
47
Tudor Investment Corp
Connecticut
$855K -$860K -14,449 -45%
Macquarie Group
48
Macquarie Group
Australia
$841K -$15.5K -260 -1%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$838K -$69.9K -1,175 -6%
Canada Life
50
Canada Life
Manitoba, Canada
$765K +$206K +3,466 +28%
1
2
3 4 5

NKTR Hedge Fund Activity: Q3 2022 in Review

230 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2022, worth a combined $561M — down 19% from $693M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NKTR positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 74 trimmed.

The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was First Trust Advisors, exiting entirely with an estimated $29.8M sold.

  • 230 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2022, up from 227 in Q2 2022.
  • Funds reported $561M of Nektar Therapeutics stock for Q3 2022, down 19% quarter-over-quarter.
  • 30 funds opened new Nektar Therapeutics positions in Q3 2022 and 25 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2022 was BlackRock, an estimated $13.8M added.
  • The largest Nektar Therapeutics seller in Q3 2022 was First Trust Advisors, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2022.